# Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout

- **Show:** The Readout Loud (STAT)
- **Published:** 23 Sep 2021
- **Source:** https://soundcloud.com/readout-loud/episode-179-scott-gottlieb-on-the-next-pandemic-another-covid-winter-aduhelms-slow-rollout
- **Transcript:** https://podcasts.opennash.com/shows/the-readout-loud/episode-179-scott-gottlieb-on-the-next-pandemic-another-covid-winter-aduhelms-sl-a646c0/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

The episode argues that the U.S. entered the Covid winter of 2021 still unprepared in ways that were foreseeable. Helen Branswell says models suggest the Delta wave could ebb after Thanksgiving, but only if no new variant appears. Scott Gottlieb argues that pandemic planning focused on flu, neglected testing, and left a CDC that lost public trust.

The main tension is between short-term hope and long-term fragility. Models are cautiously optimistic, yet booster rules are messy, global vaccine supply is thin, and public confidence in health agencies has eroded. A lighter thread follows Biogen's Aduhelm, which approval did not turn into patients: only about 100 had been treated, held back by skepticism, logistics and price.

## Key insights

1. **Planning for flu left the U.S. exposed** Gottlieb says tabletop exercises like Crimson Contagion assumed an influenza pandemic, where testing matters less because people are contagious only after symptoms. Covid spread silently, so the missing testing capacity became decisive.
2. **The national stockpile held unusable equipment** Gottlieb says stockpiled respirators did not work and masks were out of date. He calls the stockpile one metaphor for how thin the preparations were.
3. **Booster rules are loose and honor-based** The FDA authorized Pfizer boosters for people 65 and older and for many high-risk or high-exposure groups. Branswell notes no one checks eligibility, and the authorization leaves out Moderna and J&J recipients.
4. **Models see Delta fading after Thanksgiving** A modeler at NIH's Fogarty center told Branswell that the models point to cases falling to roughly 10,000 to 15,000 a day. That outlook depends on no new, more transmissible or immune-evading variant emerging.
5. **Aduhelm's launch stalled on trust, logistics and price** About 100 people had received it commercially by September 11, 2021, far below Wall Street hopes. Skeptical doctors, the need for monthly infusions, and a $56,000 average annual price all slowed it.

## Questions this episode answers

### Why was the U.S. so unprepared for Covid?

Gottlieb says planning assumed the next pandemic would be flu, so exercises and stockpiles ignored things like large-scale diagnostic testing. The CDC also botched its first Covid test and gave guidance that people found arbitrary.

### Could I have gotten a Covid booster shot in September 2021 if I wasn't high-risk?

Probably yes in practice. Helen Branswell said eligibility has always been an honor system, and she doubted a pharmacist would ask how you qualify.

### Was winter 2021–22 expected to be bad?

Branswell reported that models pointed to the Delta wave subsiding after Thanksgiving. She cautioned that a new variant able to escape immunity or spread faster could change that.

### Why wasn't Aduhelm selling well?

Only about 100 people had received it commercially by September 11, 2021. Damian Garde cited doubts about whether it works, the need for monthly infusions, and a $56,000 average annual price that left Medicare and insurers undecided.

### Does Scott Gottlieb think the CDC should be replaced?

No. He says the CDC can and must be fixed, with an operational, national-security mindset, rather than creating a new agency.

## Facts

- **Host** [0:08:13]: "Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial."
- **Host** [0:09:12]: "the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy"
- **Host** [0:08:44]: "it's an infused therapy and it's infused once a month is not necessarily in place for people to even get on it"
- **Meg Terrell** [0:04:54]: "The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID"
- **Meg Terrell** [0:04:54]: "Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters."
- **Meg Terrell** [0:04:33]: "the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it"
- **Meg Terrell** [0:05:45]: "Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later."
- **Meg Terrell** [0:06:14]: "You have to get three days of IV treatment. It suggested that can keep you out of the hospital as potentially as well as monoclonal antibodies."
- **Host** [0:06:44]: "oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development"
- **Helen Branswell** [0:14:45]: "the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that."
- **Helen Branswell** [0:16:07]: "this EUA only covers the Pfizer vaccine. And just under half of the American population that's been vaccinated got the Pfizer vaccine."
- **Helen Branswell** [0:17:25]: "there was never any requirement that you prove that you were a diabetic or that you had hypertension"
- **Meg Terrell** [0:18:34]: "A lot fewer vaccinated Trump voters plan to get a booster than vaccinated Biden voters."
- **Helen Branswell** [0:22:58]: "India was going to be the producer for much of the developing world. And then India got swamped by the Delta virus"
- **Meg Terrell** [0:22:01]: "he also is really taking aim at the companies, Moderna and Pfizer in particular, for not sharing their expertise and their patents"
- **Host** [0:25:35]: "which also includes board member of Pfizer and Illumina, senior fellow at the American Enterprise Institute and CNBC contributor."
- **Host** [0:26:38]: "all of the tabletop exercises that we had done, and I had been a part of some of those, prepped for a potential pandemic with an influenza, including crimson contagion, which happened just before COVID ended up striking."
- **Host** [0:27:08]: "Respirators that we had stockpiled didn't work. The masks were out of date."
- **Host** [0:27:08]: "if you look back at the pandemic tabletop exercises like crimson contagion, diagnostic testing wasn't a big part of those exercises."
- **Host** [0:28:06]: "they botched the development of the first SARS-CoV-2 test. They failed to come up with a plan for widespread testing"
- **Host** [0:29:02]: "we should be creating a new agency or creating a new Department of Homeland Security that's focused on pandemic planning like we did after 9-11."

## Transcript

**[0:00:15] Meg Terrell:** Welcome to this week's episode of The Readout Loud, a weekly biotech podcast from STAT. I'm Meg Terrell.

**[0:00:20] Host:** I'm Adam Feuerstein. And I'm Damian Garde.

**[0:00:22] Meg Terrell:** It's Thursday, September 23rd. And here's what we're going to talk about this week.

**[0:00:26] Host:** We gave Adam a break from COVID-19 talk last week, so naturally we have to double up this week. And for good reason. Our colleague Helen Branswell has an incredible story out this week about what this winter may have in store. She joins us to discuss it. I appreciate that, Damien. Next up, you've heard his advice for grilling. But did you know that former FDA Commissioner Dr. Scott Gottlieb has also some thoughts on the pandemic? His new book was released Tuesday, and we go in depth with him on what went wrong, beyond the obvious, and how to prevent this from happening again.

**[0:00:54] Meg Terrell:** We'll start with a look at the week in biotech.

**[0:00:56] Host:** But first, a word from our sponsor.

**[0:01:07] Meg Terrell:** Hi, everyone. My name is Maria. My name is Danielle, and Maria and I are the new hosts of Genentech's award-winning podcast, Two Scientists Walk Into a Bar. It's a show for scientists, science geeks, and the people who love them. Aww. So Maria, true story, is from the UK. She's into clinical data, transcription factors, and long runs on the beach. That's right! And Danielle is from Texas. She loves translational medicine, woodworking, and getting up close and personal with cancer cells.

**[0:01:39] Meg Terrell:** And when we're not botching each other's accents, you can usually find us chatting up other scientists about all kinds of cutting-edge research. So grab a drink and check us out wherever you get your favorite podcasts or find us at gene.com slash podcast. That's G-E -N-E dot com slash podcast. So Adam, let's start by talking about what you did last night. It would normally not be something so exciting, but now it is.

**[0:02:09] Host:** I know. I had fun. Yeah, I discovered these places called bars. It's a bar and you go and there's drinks and then there's a band who's playing live music.

**[0:02:19] Meg Terrell:** Those all sound like terrifying things.

**[0:02:21] Host:** It was a great time. I actually went out last night to see a friend's band called Graveyard of the Atlantic to give them a little bit of a plug. They're a local Boston band. And they actually have a biotech connection because their lead guitarist, Dave DeBaney, is married to Minisha Pai, who does IR at Vertex Pharmaceuticals. So shout out to those guys. And we had a great time last night. It was my first bar experience post-COVID, or not post-COVID, but since COVID.

**[0:02:53] Host:** During COVID, since COVID.

**[0:02:54] Meg Terrell:** So what were the vaccine requirements? Who was wearing masks? How did you drink a drink through a mask?

**[0:02:59] Host:** Yeah, that was kind of an interesting thing. So when you got, and this is like a divy bar, but when you got to the bar, the woman, the very nice woman who was working the door, took my $5 cover charge, also asked me for proof of vaccination. So I showed her a photo of my vaccine card. And, you know, she didn't card me, thank God, because I'm, you know, 500 years old. But yeah, then then you're in and you have to wear masks.

**[0:03:24] Host:** So you wear masks in the bar.

**[0:03:26] Meg Terrell:** So, like, did you drink anything? Like, what do you put a straw through the side of your N95?

**[0:03:32] Host:** Yeah, that was that was kind of the weird thing because I kept I did drink. I had a couple of beers and yeah, I had to keep pulling the mask down to to drink, obviously. But all in all, it was really fun. And it's something that I look forward to doing more of as we get rid of COVID, hopefully. So speaking of being rid of COVID or ideally being rid of COVID, the big news this week, I guess on that front, was this ongoing situation with booster doses and who ought to get them and when they might be available and which governmental authority gets to decide that.

**[0:04:07] Host:** So Meg, where are we as of the moment of this recording?

**[0:04:10] Meg Terrell:** Well, this is Thursday morning. So we are halfway through CDC's advisory committee's two-day meeting on this very topic. And as my husband put it last night, as I was like fielding phone calls or trying to make dinner, just working like a long day covering this entire thing. And the FDA was like rumored to be coming out with its decision. He was like, there are so many steps in this process and all of them are breaking news.

**[0:04:33] Meg Terrell:** I was like, you just basically described the last year and a half of my life. But he's right. I mean, it's kind of absurd. He's like, didn't the FDA already decide on this on Friday? And I was like, no, that was just its advisory group. And then the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it. And then we get to use the booster shots. So that's essentially where we are now.

**[0:04:54] Meg Terrell:** The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID and people who have high risk of exposure through their jobs and thus are at higher risk of severe outcomes of COVID. And Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.

**[0:05:19] Meg Terrell:** So the FDA kind of saying who they think this should be given to, that's the purview of the CDC's advisory committee. So we'll hear their recommendations Thursday afternoon and a vote as well. And then this basically gets, you know, available ostensibly only to people who got Pfizer the first time around. But as we talk about with Helen Branswell later in the episode, it may not be that cut and dry. There was also a ton of other COVID news this week.

**[0:05:45] Meg Terrell:** Monday morning, we woke up to Pfizer's results for kids ages 5 to 11. And so we're now we're talking about a vaccine for kids by Halloween. Tuesday, we woke up to Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later. They talked about their second shot six months later. But don't worry, guys, the first dose still provides long lasting protection was essentially the gist of that.

**[0:06:14] Meg Terrell:** Whether we start to hear more about J &J getting used around the world as a single shot vaccine is an open question and probably a very important one. And then we got some news on remdesivir being used on people who are not yet hospitalized. You have to get three days of IV treatment. It suggested that can keep you out of the hospital as potentially as well as monoclonal antibodies. But it was kind of a funny study.

**[0:06:37] Meg Terrell:** They stopped enrolling early in April. And who's going to get three days of IV treatment? You know.

**[0:06:44] Host:** Yeah. The remdesivir news, I mean, to your point, that's not a very practical thing for someone who is not hospitalized, who's recently diagnosed. But to the extent there's a silver lining, like we already know that the monoclonal antibodies, as you mentioned, do a similar job and are more convenient. But remdesivir being effective as an antiviral could be a good sign for the oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development.

**[0:07:13] Host:** They don't have the same mechanism per se, but just the notion that remdesivir could have an effect in that stage, it could be, you know, reason for optimism about these infinitely more convenient oral treatments that are coming through the pipeline. And shifting gears, Damien, you and I were busy writing a story about, or we're taking a closer look at a certain Alzheimer's drug. That's right. So, yeah, Aduhelm, the star of this podcast, or I guess co-star to COVID-19, that's probably too glib.

**[0:07:42] Host:** But anyway.

**[0:07:43] Meg Terrell:** I thought I was the star of this podcast.

**[0:07:46] Host:** So, yeah. So, you know, we learned from Biogen a couple weeks ago that the commercial launch of Aduhelm, their infinitely discussed treatment for Alzheimer's disease, was going more slowly than the company had anticipated and thus than really everyone else had, or at least Wall Street had. What they didn't mention in that disclosure was just how many patients had been treated with the drug. And you and I learned that. 100 patients. Right. Right. Which is a small number.

**[0:08:13] Host:** I mean, to put it in context, you know, Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial. And based on basically Wall Street's estimates of how much money Biogen would make on Aduhelm in 2021, basically they thought thousands of patients would be getting the drug by now. The fact that it's only about 100 is really cause for a lot of pondering and a lot of revisiting expectations.

**[0:08:44] Host:** And, you know, Biogen came clean, I think, a little bit about what the challenges are. And they're basically, one, a lot of people, physicians, scientists, and even some patients, are really skeptical as to whether this drug works for the reasons that we've discussed for months and months and months and months. But then furthermore, the infrastructure to it's an infused therapy and it's infused once a month is not necessarily in place for people to even get on it, even if they are prescribed the drug.

**[0:09:12] Host:** And then three, the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy, has led to hospital groups, insurers, and largely Medicare really in a tough spot in deciding whether to pay for this. And so, you know, Medicare is deliberating. A lot of groups are deferring to them. And basically Biogen is kind of caught in this position where they got what they wanted in the form of this FDA approval.

**[0:09:44] Host:** But a confluence of factors, some of which are under their control and some of which are not, have made it to where this drug is just not really ending up in patients.

**[0:09:51] Meg Terrell:** As your next scoop on Aduhelm, I would like you guys to focus in on how they reached the $56 ,000 price and if it was a push from the board or if it was some other.

**[0:10:02] Host:** All right, we'll work on that.

**[0:10:04] Meg Terrell:** Thanks, guys. Winter is coming.

**[0:10:18] Host:** Again. That is the lead of a new story from our colleague Helen Branswell, which continues, a year ago, experts warned that the United States faced a grim winter if Americans didn't mask up and social distance to slow transmission of the SARS-CoV-2 virus before indoor weather, aka winter, settled in for its long stay. We all know how well that warning was heated. In January, cases topped 300 ,000 a day and COVID ended the lives of about 95 ,000 Americans before the month was out.

**[0:10:46] Host:** And joining us to discuss the fact that winter is coming is Helen Branswell. Helen,

**[0:10:51] Meg Terrell:** thanks for joining us again. Hi, good to be with you. So Helen, I just absolutely love this story that you wrote this week, because I feel like experts so infrequently are willing to actually talk about what could happen. And you managed to get a lot of really fantastic ones to talk with you about that for this upcoming winter. And of course, you know, the most predominant feeling is uncertainty. But you also quoted some modelers who say things could be looking up from here.

**[0:11:20] Meg Terrell:** Can you tell us about that? Let's start with a little hope.

**[0:11:24] Helen Branswell:** Sure. So I was, you know, quite uncertain about what to think would be coming this winter myself. So I did reach out to a bunch of people. And one of the people I spoke to was Cécile Vibault, who is an epidemiologist and modeler who works at the Fogarty International Center at the National Institutes of Health. she and a group there are monitoring nine modeling efforts on an ongoing basis and what she said is that the models point to the delta wave sort of subsiding in this country in late November sort of just after Thanksgiving and getting to the point where transmission could be quite low sort of down into the 10 to 15 ,000 cases a day range.

**[0:12:16] Helen Branswell:** And she said, you know, once it gets down there, it could stay there for a while with the big caveat of, you know, as long as there is no new variant that is able to either escape immunity or become more transmissible still than the Delta

**[0:12:34] Host:** variant. And Helen, obviously Thanksgiving and Christmas are big travel periods for Americans. Does her model factor in the fact that people will be traveling during that time period?

**[0:12:45] Helen Branswell:** Yeah, absolutely. I mean, last year, you know, we really saw the effect of people getting together for Thanksgiving and Christmas in the disease levels that happened after that period. Yes, the models do factor that in. They do look fairly promising as long as there are new variants coming at us in the near term.

**[0:13:07] Host:** So, you know, happening really as we speak is the debate, which seems somewhat settled over just when and for whom booster shots of COVID-19 vaccines will be available in the United States. How does that factor into how epidemiologists and others are looking at this winter, knowing that, you know, some millions of people will be able to get third doses of vaccine?

**[0:13:33] Helen Branswell:** I think this modeling work that we've been talking about, I'm not sure that it factors in third doses. I think it's looking at sort of the amount of immunity there is in the population, both from existing doses that have been administered and the amount of infection that has occurred in the country. But obviously, if people start to get third doses, immunity rates will go up, and that would contribute to lessening spread of the virus.

**[0:14:03] Meg Terrell:** So let's talk about the news this week about the boosters. Helen, I was following your live tweeting of the CDC's Advisory Committee on Immunization Practices meeting on Wednesday, and we're recording this Thursday morning. So we're expecting to get their vote this afternoon by the time a lot of people are listening to this. But on Wednesday night, the FDA authorized Pfizer's booster. And on Twitter, before that happened, you noted, it seems pretty clear that the rollout of a booster shot program is going to be messy as hell.

**[0:14:35] Meg Terrell:** I think a lot of people agree with you. What's your take on essentially where we are, where this authorization came down and what this is going to look like?

**[0:14:45] Helen Branswell:** So, you know, what FDA said in the final analysis was pretty interesting. Um, the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that. But FDA hasn't actually, you know, outright gone against Virpac, but at the same time, they have added so many groups to this EUA that a lot of people who want boosters are going to find a way to get a booster as a consequence of this EUA.

**[0:15:25] Helen Branswell:** What they've said is that people who are 65 and older qualify, as do people who are at high risk from COVID, either because of exposure to the disease, which covers health care workers, teachers, daycare workers, people who work in grocery stores. I mean, it's a long list of people who can fit in under the exposure category. And then also people who are at high risk because of health conditions. And again, that's another long list of people, people who are obese, people who have diabetes.

**[0:16:07] Helen Branswell:** there's a long list of people who could now go to their pharmacy and say, I need to be boosted because I fit into the parameters of this EUA. Where it's going to get messy is that this EUA only covers the Pfizer vaccine. And just under half of the American population that's been vaccinated got the Pfizer vaccine. So there's nothing here for people who got Moderna or people who got Johnson & Johnson. But it's, you know, widely known that some of those people have been seeking boosters anyway and may decide that they won't wait for the FDA to authorize boosters of the Moderna vaccine or the J &J vaccine.

**[0:16:54] Helen Branswell:** and they may just go get themselves a, you know, a Pfizer booster, sort of going for a mix and match approach to their vaccine regimen.

**[0:17:03] Host:** Is there anything stopping people who maybe don't fit those categories from getting a booster shot? Like I'm thinking about myself, like I'm probably not in any of those categories, although I have put on quite a bit of COVID weight. But like, if I want to go to CVS and get a booster shot, can I go get one?

**[0:17:25] Helen Branswell:** I don't know what would stop you, Adam. I mean, it's always been an honor system. You know, for instance, during the initial rollout, when they, the only way anybody could stop anybody at that point was based on age. Once you get into, you know, categories where people who had certain health conditions could step forward, you know, there was never any requirement that you prove that you were a diabetic or that you had hypertension or that you had any number of the conditions that were listed as putting you in a priority group.

**[0:18:05] Helen Branswell:** So, you know, I doubt very much if a pharmacist is going to ask you, you know, how do you qualify? If you book the appointment, I think they're going

**[0:18:14] Host:** to give you the vaccine. And just like a related question, is there any researchers, anyone looked in kind of how willing Americans are to get a booster shot. I mean, obviously, getting vaccinated the first time has been very polarizing in this country. Has anyone done looked into that and said, like, how willing will people be to get a third shot? I can answer that question. So we've

**[0:18:34] Meg Terrell:** done some polling on it. And it sounds like people who already were vaccinated, about three quarters of those folks say they plan to get a booster shot. But then if you look at it by who you voted for in 2020, because everything is looked at through a political lens. And unfortunately, this provides illuminating information. A lot fewer vaccinated Trump voters plan to get a booster than vaccinated Biden voters. And even President Trump, who himself is vaccinated, he expressed ambivalence about getting a booster.

**[0:19:04] Meg Terrell:** And I don't know how much that influences people. But it seems like even folks who are like really on board with getting the vaccine the first time around, maybe sort of changing their minds about it or not feeling so eager to get a booster shot. But But for the most part, it does sound like most people who got vaccinated will get a booster.

**[0:19:20] Helen Branswell:** Yeah, that doesn't surprise me. I would say, though, you know, that if if the models are right and if we start to see the delta wave coming under control in the country, that probably will also depress uptake of boosters. You know, people are motivated to get vaccinated when they're afraid of what's before them.

**[0:19:38] Host:** So zooming out from the United States, where we're all debating whether to get a third dose, obviously, much of the world is desperate for access to even a first one. And there was something of a hopeful note in your story. You spoke to Barney Graham, formerly of the NIH, who was hoping that, you know, between Delta and some of the other epidemiological trends, that conceivably the virus is trapped right now. And so if we can immunize as many people as possible around the world, we could be looking at, you know, kind of cresting the wave of this virus.

**[0:20:11] Host:** And so I guess my question is, you know, where are we on the global distribution of vaccine process versus, you know, like how many months might we be away from from reaching something like herd immunity on a global scale?

**[0:20:25] Helen Branswell:** Oh, that's a long way off. I'm sorry to be a downer at this point, but many, many countries have still vaccinated a very small proportion of their people. There are still far too few vaccines available to low and middle income countries. uh the you know part of the problem is the vaccine that you know in our part of the world has been produced to the largest degree is the Pfizer vaccine and it's the hardest one to deliver um so you know in places where um cold chain is is not necessarily um robust you know this is a very hard vaccine to get out into the last mile.

**[0:21:14] Helen Branswell:** You probably will remember that COVAX, which is the enterprise that the World Health Association, CEPI and Gavi, have partnered on to try to procure vaccine doses for countries that can't buy them for themselves. They recently downgraded their estimate of how much vaccine they're going to be able to provide this year. And, you know, that may not be the end of that story. I mean, I don't know that I actually think herd immunity can exist on a global scale, but, you know, we're nowhere near bringing this virus under control across the world.

**[0:22:01] Meg Terrell:** Alan, I'm curious to know, you know, we've seen Dr. Tom Frieden, the former CDC director, really come out pretty strongly about this issue in the last week or two, taking aim both at the Biden administration for not doing enough, not just in terms of donating vaccines, but also equipping nations to whom are donating them with the cold chain requirements and helping pay vaccinators or things like that. But he also is really taking aim at the companies, Moderna and Pfizer in particular, for not sharing their expertise and their patents and helping set up manufacturing in these countries.

**[0:22:37] Meg Terrell:** I'm just wondering, you know, we had the Pfizer CEO, Albert Bourla on CNBC on Wednesday and asked him about that because they say it's a mid to long term goal of setting up MRNA manufacturing in these other places. How do you just reconcile what you're hearing from both sides about that? How do you think about it?

**[0:22:58] Helen Branswell:** Well, I don't think there's a quick or easy fix. I mean, you know, what has become very clear in this pandemic is that people will take care of their own. And so the world definitely needs a lot more capacity and a lot more capacity spread out. You know, India was going to be the producer for much of the developing world. And then India got swamped by the Delta virus and India has an exported vaccine. You know, that was actually a foreseeable problem.

**[0:23:31] Helen Branswell:** You know, there were people who were talking about the need to produce in small population countries because countries would close borders, you know, if things got bad. going forward, you know, I think there's going to be a huge push to disseminate capacity to produce around the world. I suspect, you know, at least some of that is going to be based on the mRNA platform, but it may not all be. And frankly, you know, what would be really useful at this point is if some of the other vaccines that are much easier to administer could be pushed out in greater degrees.

**[0:24:13] Helen Branswell:** You know, J &J, still not a lot of product there, but that vaccine could be very useful internationally. The AZ vaccine, you know, AstraZeneca, that vaccine will be really useful in an international setting. If Novavax can manage to consistently produce vaccine to high levels. Everybody has huge hopes for that vaccine. Having some other options available would be really, really helpful. And hopefully that will start to happen soon.

**[0:24:52] Host:** Helen, thanks for joining us again.

**[0:24:53] Helen Branswell:** Thanks for having me, guys.

**[0:25:06] Host:** The virus didn't arrive with a group of visitors from China where it originated, or from Italy, where it established its next major foothold. Instead, it likely rode along the breadth of probably hundreds of different travelers from a variety of locations, each ferrying the infection and evading the poorest controls that the federal government had put in place at U.S. airports. At the time, nobody knew what was happening. No one knew how much virus was being carried by people who showed no outward symptoms of the disease.

**[0:25:35] Host:** These were people who might never manifest any signs of illness, but were still contagious. Without the ability to test people for the virus, we had no way of detecting its spread. We certainly had no way of stopping it. Former FDA Commissioner Dr. Scott Gottlieb can now add published author to his long list of titles, which also includes board member of Pfizer and Illumina, senior fellow at the American Enterprise Institute and CNBC contributor. His book about the pandemic, Uncontrolled Spread, Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic was released Tuesday.

**[0:26:06] Host:** You just heard him reading an excerpt from it. And he joins us now to talk about it. Dr. Gottlieb, welcome back to the Readout Loud. Thanks for having me.

**[0:26:12] Meg Terrell:** So Scott, one of the themes in your book is how we thought we were prepared for something like this. But you point out that all those plans turned out to be what you call a technocratic illusion, which is just such an evocative phrase. Our stockpile was drastically insufficient. And at the core of the issue, you write that we prepared for the wrong pathogen. So why was the U.S. so convinced that the next pandemic would be a flu?

**[0:26:35] Meg Terrell:** And why were we so unable to pivot when it turned

**[0:26:38] Host:** out to be something different? Well, all of the tabletop exercises that we had done, and I had been a part of some of those, prepped for a potential pandemic with an influenza, including crimson contagion, which happened just before COVID ended up striking. And, you know, if you're looking at pandemic preparedness through the lens of a potential pathogen like influenza, the types of things you worry about and focus on are different. First of all, the preparations that we had made for a flu were inadequate.

**[0:27:08] Host:** And the stockpile is just one metaphor for that inadequacy, where we had things in the stockpile that simply didn't work. Respirators that we had stockpiled didn't work. The masks were out of date. Certain contingencies that become very important in preparing for a coronavirus aren't as important when it comes to flu. So for example, diagnostic testing isn't going to be an essential component to actually responding to a pandemic with flu. And if you look back at the pandemic tabletop exercises like crimson contagion, diagnostic testing wasn't a big part of those exercises.

**[0:27:37] Host:** There was no difficulty getting access to screening because with an influenza, the incubation period is very short and people are typically contagious. after they manifest symptoms. So getting people diagnosed while they're asymptomatic as a way to control the spread of the pathogen isn't as critical. And also the nation's installed base of testing equipment that's in every doctor's office that can test for influenza A or influenza B would be sufficient. You wouldn't have to do PCR testing and get the exact viral sequence of the strain that was infecting them.

**[0:28:06] Host:** So you had an installed base of testing. So by looking at pandemic preparedness through the lens of influenza, things that became very important for a coronavirus were relegated when it came to trying to prep for a pandemic with influenza. So, Scott, in the book, you know, you're very critical of the Centers for Disease Control and Prevention. You point out that in the early days of the pandemic, the agency, you know, they botched the development of the first SARS-CoV-2 test.

**[0:28:32] Host:** They failed to come up with a plan for widespread testing and actually impeded rather than assisted the development of tests by outside commercial labs. And you also criticize the CDC for some of its public health guidelines, like establishing the six foot social distancing requirement, you know, without evidence that that would help. So I guess the question here is, you know, can the CDC be fixed and should it be fixed? Meaning, should we be relying on the CDC in future pandemics or should the responsibilities for surveillance and response go somewhere else?

**[0:29:02] Host:** I think it can be fixed and I think it has to be fixed. I don't think that when we engage in pandemic planning going forward and we come together and have a commission and try to reach a bipartisan consensus on what the new framework is going to look like, that we should be creating a new agency or creating a new Department of Homeland Security that's focused on pandemic planning like we did after 9-11. And I think we need to vest these kinds of capabilities within CDC.

**[0:29:24] Host:** But it's a reimagined CDC. It's a CDC that has an operational focus, has a national security mindset that isn't so retrospective, that's comfortable surfacing real time information to inform active policy decision making, even if it isn't certain. An even more fundamental challenge that we're going to face, in my view, at least, is that there is now a large portion of the population that has lost confidence in public health decision making in the setting of a crisis that has lost confidence in the guidance that was issued, that felt that the recommendations were arbitrary, that they were inconsistent, that they weren't articulated in a way that people could find practical value from the issues of should I wear a mask?

**[0:30:06] Host:** Shouldn't I wear a mask? Things seemed arbitrary. They didn't seem science based in many cases because they were arbitrary and they weren't grounded on good science. And the agency wasn't transparent about how speculative some of the recommendations were at the time that they were being made. And so people have now lost confidence in public health officials to issue guidance in a setting of a crisis. And this is this breaks down along ideological lines for sure. I mean, there is a right left divide on this, but it is much broader than that.

**[0:30:31] Host:** I think it transcends just pure politics. And so we're going to need to earn back the public's trust and convince them that public health agencies should be empowered in a setting of a public health crisis before we even have the discussion about how then to empower public health agencies going forward in the setting of a public health crisis. And it's going to require some self-awareness on the part of public health officials that there were certain aspects of what we did that also failed.

**[0:30:57] Host:** So sort of on that point, you know, your book does focus mostly on the agency level and you deliberately avoid framing too many of the failures in political terms. But so many of the decisions in question, whether federal, state or local, are made by elected officials. And so considering that voting is pretty much the only thing most readers of your book can do to influence the nation's future pandemic preparedness, what should we be saying to our leaders and our political candidates?

**[0:31:22] Host:** Like, what would a pandemic smart platform look like? Yeah, I think that voters should care about public health and voters should care about candidates being willing to invest in strong public health measures, strong public health infrastructure. And that transcends just pandemic preparedness. I mean, this pandemic showed how excessively vulnerable our society is because of systemic challenges that we face with getting adequate health care to communities in society that were made excessively vulnerable to COVID precisely because they lacked access to care.

**[0:32:01] Host:** They faced bias in how care was delivered. They worked in jobs where they didn't have the social capital at work to demand conditions that would keep them safe. Something as simple as a mask on the job, a high quality mask, if you were working in a confined space that was conducive to spread. So I think voters should care about politicians being willing to take strong positions on trying to reinvigorate the nation's public health. That's why I say, you know, we have to have this discussion about how to properly empower resource the CDC, how to change its orientation, how to give it more of a national security mindset.

**[0:32:36] Host:** But all of that is predicated on a belief that you think public health institutions should be strong. And there's a lot of people who are very skeptical of that notion. And it's a lot of conservatives. It's a lot of, you know, my my my fellow conservatives, but it's broader than that. And that really worries me. Building back that consensus, I think, is going to be difficult.

**[0:32:55] Meg Terrell:** Well, I wonder what do you see as your role in helping accomplish that? You have this unique position now. You were in government. You're no longer in government. You sit on many different seats of power and access. Do you ever think about going back in? Would you be a sort of pandemic preparedness czar? Are you the person to coordinate this on the government level or are you more effective from this sort of more private sector role you've now taken on?

**[0:33:24] Host:** I haven't really thought about how I could be effective or where I could be most effective from in this debate. I mean, I look at this through the lens of where I am right now, and I think I could be effective in trying to just articulate why it's important, why it's important that we have strong public health institutions that are able to execute this kind of a mission. It's not just about building a better CDC, but it's about looking at why certain communities were made excessively vulnerable and how do we rectify that.

**[0:33:55] Host:** What's your access like today with the Biden administration? Obviously, you know, in the book, you talked about having like a lot of access being at the White House under the Trump administration. You know, what is it like under a Democratic president today? Are they are people listening to you? I have dialogue with with members of the Biden administration. I've had pre-existing relationships with a number of people who are in in roles right now where they have involvement in the response to COVID.

**[0:34:20] Host:** And I maintain those relationships and maintain that dialogue. I'm going to preserve the, you know, the discretion of the people who reach out to me and talk to me from time to time or on a more routine basis. But I feel that if I have a strong opinion on something that the Biden administration, people in the Biden administration who are in positions of authority and able to, you know, execute on aspects of this response are willing to take my call.

**[0:34:46] Host:** And I'm very grateful for that. So last question, you know, in the book, or rather you dedicate the book to your three daughters. And, you know, as we mentioned before, you were on CNBC most days, sometimes starting at 6 a.m. Throughout that whole pandemic, you're on several boards. You have, I think, at least two day jobs at AEI and NEA. And then plus you wrote a book. So I guess this is the sort of like talk show question.

**[0:35:08] Host:** But how did you do it? All my free time was spent writing this book. And that's why I dedicated the book to my family, because I really was absent over the last year. I mean, I spent every moment that I had that I wasn't engaged in something where I had to, you know, work on behalf of NEA. or something related to AI or Pfizer or some of the other business engagements that I have writing this book.

**[0:35:36] Host:** So it consumed all my free time.

**[0:35:37] Meg Terrell:** Well, I bet they're excited that you'll be done with book publicity soon and they'll get to hang out with daddy.

**[0:35:42] Host:** Thanks, Meg. That does it for another episode of The Readout Loud. Thank you to Teresa Gaffney for producing this week's episode.

**[0:35:59] Meg Terrell:** Our senior producers are Hyacinth Empanado and Alyssa Ambrose.

**[0:36:02] Host:** Our executive producer is Rick Burke. And our theme music is by Brian Joel.

**[0:36:06] Meg Terrell:** And we'd love to hear from you. Tell us what you like about this week's episode, what you didn't like, and how you drink through a mask. You can do all that by sending us an email at readoutloud at statnews.com.

**[0:36:16] Host:** And if you like what we do, leave a review or a rating on Apple Podcasts or whichever platform you use to get your podcasts. See you next week. Thank you.
